Recent advances in targeting LRRK2 for Parkinson’s disease treatment
Mahsa Karami(Kermanshah University of Medical Sciences), Zhila Izadi(Razi University), Mehregan Babamohamadi(University of Tabriz), Pantea Majma Sanaye(Zanjan University of Medical Sciences), Roshanak Amirian(Kermanshah University of Medical Sciences), Pouya Goleij(The University of Sydney)
Cited by 14
Related Papers
Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
|The Lancet Rheumatology|2024|209
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
|Cell Death and Disease|2024|83
Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
|Frontiers in Molecular Biosciences|2022|31
Types of RNA therapeutics
|Progress in molecular biology and translational science|2024|14